McKesson Corporation (MCK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 231 | 238 | 264 | 277 | 309 | 359 | 403 | 411 |
| Operating profit | $bn | 6 | 7 | ||||||
| Net profit | $bn | 1 | -5 | 1 | 4 | 3 | 3 | 5 | 5 |
| EPS reported | $ | 38.38 | 37.37 | ||||||
| Operating cashflow per share | $ | 49.80 | 57.73 | ||||||
| Capex per share | $ | 6.03 | 1.85 | ||||||
| FCF per share | $ | 43.77 | 55.88 | ||||||
| Free cash flow | $bn | 6 | 6 | ||||||
| Net debt | $bn | 2 | 5 | ||||||
| Book value equity | $bn | -2 | -4 | ||||||
| Book value per share | $ | -17.50 | -35.57 | ||||||
| Number of shares | m | 124.1 | 119.2 | ||||||
| DPS (TTM paid) | $ | 2.58 | 3.40 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.42 | 23.19 | ||||||
| P/B LTM | x | -49.24 | -20.22 | ||||||
| P/S LTM | x | 0.23 | 0.21 | ||||||
| P/FCF LTM | x | 18.70 | 13.86 | ||||||
| EV/EBITDA LTM | x | 12.98 | 12.24 | ||||||
| EV/Sales LTM | x | 0.26 | 0.26 | ||||||
| Earnings Yield LTM | % | +7.02% | +4.31% | ||||||
| FCF Yield | % | +5.35% | +7.21% | ||||||
| Quality | |||||||||
| ROE | % | -219.24% | -194.39% | ||||||
| ROIC | % | +31.48% | +27.91% | ||||||
| Operating margin | % | +1.60% | +1.62% | ||||||
| Gross margin | % | +3.61% | +3.64% | ||||||
| FCF/Sales | % | +1.34% | +1.61% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +49.22% | +66.90% | ||||||
| Sales Growth YoY | % | +12.36% | +33.03% | ||||||
| Net Income Growth YoY | % | +44.52% | +52.96% | ||||||
| FCF Growth | % | +9.43% | +70.53% | ||||||
| Operating Profit Growth | % | +47.62% | +69.44% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.36% | +0.38% | ||||||
| Dividend Growth | % | -15.69% | +27.82% | ||||||
| Payout Ratio | % | +8.00% | +8.58% | ||||||
| FCF/Debt | x | 0.66 | 0.53 | ||||||
| Net Debt/EBITDA | x | 0.65 | 0.91 | ||||||
| EBIT/Net interest | x | 26.13 | 43.49 | ||||||
| Net debt/market cap | % | +5.96% | +9.56% | ||||||
| Net debt/Equity | x | -1.10 | -1.08 | ||||||
| Gross debt/equity | x | -3.97 | -2.76 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free